ONKOLOGIE www.onkologiecs.cz 32 MONOKLONÁLNÍ GAMAPATIE Plazmocelulární malignity (mnohočetný myelom, solitární plazmocytom a plazmocelulární leukemie), přehled klinických příznaků, diagnostických kritérií a léčby 159. Adam Z, Král Z, Klimeš J, Boleloucký Z, Pour L. Chronický stres, psychická nepohoda a deprese zvyšují četnost infekčních, autoimunitních, ale i maligních nemocí. Vnitř lék. 2020;66(1):34-38. 160. Adam Z, Klimeš J, Pour L, et al. Maligní onemocnění, psychika a stres: příběhy pacientů s komentářem psychologa. Praha: Grada Publishing; 2019. 161. Klimeš J, Adam Z. Dysthymie – lidé s temnou duší a jejich blízcí. Novela Bohemica; 2022. 162. Durie BGM, HoeringA, Abidi MH, et al. Bortezomib, lenalidomide anddexamethasone vs. lenalidomide anddexamethasone induction followed by lenalidomide and dexamethasonemaintenance in patients with newly diagnosedmyelomawithout intent for immediate autologous stemcell transplant: results of the randomised phase III SWOG trial S0777. Lancet. 2017;389:519-527. 163. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311-1320. 164. Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018;32:383-390. 165. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood. 2000;96:2037-2044. 166. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Clinical course of solitary extramedullary plasmacytoma. Radiother Oncol. 1999;52:245-249. doi: 10.1016/S01678140(99)00114-0. 167. Nahi H, Genell A, Walinder G, et al. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. Eur J Haematol. 2017;99:216-222. doi: 10.1111/ejh.12907. 168. Ozsahin M, Tsang RW, Poortmans P, et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients. Int J Radiat Oncol Biol Phys. 2006;64:210-217. doi: 10.1016/j.ijrobp.2005.06.039. 169. Glasbey JC, Arshad F, Almond LM, et al. Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. Ann R Coll Surg Engl. 2018;100(5):371-376. doi: 10.1308/rcsann.2018.0015. 170. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:6. doi: 10.1100/2012/895765. 171. Weber DM. Solitary bone and extramedullary plasmacytoma. ASH Education Program Book. 2005;2005:373-376. 172. Boll M, Parkins E, O’Connor SJM, Rawstron AC, Owen RG. Extramedullary plasmacytoma are characterized by a ‘myeloma-like’ immunophenotype and genotype and occult bone marrow involvement. Br J Haematol. 2010;151:525-527. doi: 10.1111/j.1365-2141.2010.08386.x. 173. Hill QA, Rawstron AC, de Tute RM, Owen RG. Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis. Blood. 2014;124:1296-1299. doi: 10.1182/blood-2014-04-566521. 174. Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;6. doi: 10.1100/2012/895765. 175. Caers J, Paiva B, Zamagni E, et al. Diagnosis,treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018;16;11(1):10. doi: 10.1186/s13045-017-0549-1. 176. Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, Samson D. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124:717-726. 177. Tsang RW, Gospodarowicz MK, Pintilie M, et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys. 2001;50:113-120. doi: 10.1016/S0360-3016(00)01572-8. 178. Tsang RW, Campbell BA, Goda JS, et al. Radiation Therapy for SolitaryPlasmacytoma and Multiple Myeloma: Guidelines From the International LymphomaRadiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018;101(4):794-808. doi: 10.1016/j.ijrobp.2018.05.009. 179. König L, Herfarth K. Nutzen der Radioonkologie beim solitären Plasmozytom oder multiplen Myelom [Benefits of radiotherapy for patients with solitary plasmacytoma or multiple myeloma]. Radiologie. 2022;62(1):30-34. German. doi:10.1007/s00117-021-00935-y. 180. Pika T, Minařík J, Prášil V, et al. Solitární kostní plazmocytom. Osteologický bulletin. 2012;17(4):136-142. 181. Bačovský J. Solitární plazmocytom Interní medicína pro praxi. 2005;7(10):444-446. 182. Hrabovský Š, Řehák Z, Stálík J, et al. Raritní případ mnohočetného myelomu: vícečetný solitární plazmocytom kostí bérců a předloktí. Vnitř lék. 2015;61(2):161-165. 183. Pham A, Mahindra A. Solitary Plasmacytoma: a Review of Diagnosis and Management. Curr Hematol Malig Rep. 2019;14(2):63-69. doi:10.1007/s11899-019-00499-8. 184. Kyle RA, Maldonado JE, Bayrd ED, et al. Plasma cell leukemia. Report on 17 cases Arch. Intern. Med. 1974;133(5): 813-818. 185. Granell M, Calvo X, Garcia-Guinon, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica. 2017;102(6):1099-1104. 186. Ravi P, Kumar A, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma Blood Cancer J. 2018;8(12):116. doi 10.1038/s41408-018-0140-1. 187. Fernandez de Larrea C, Kyla RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group Leukemia. 2013;27(4): pp. 780-791. 188. Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192. doi:10.1038/s41408-021-00587-0. PMID: 34857730. 189. Gowin K, Skerget S, Keats JJ, et al. Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment. Leuk Res. 2021;111:106687. doi: 10.1016/j.leukres.2021.106687. 190. Jung SH, Lee JJ. Update on primary plasma cell leukemia. Blood Res. 2022;57(S1):62-66. doi: 10.5045/br.2022.2022033. PMID: 35483928. 191. Matýšková M, Krahulcová E, Buliková A. Pohrudniční výpotek při plazmacelulární leukémii. Vnitř lék. 1995;41(7): 467-469. 192. Žárská M, Vrábel D, Bezděková R, et al. Plazmocelulární leukemie – zapomenutá nemoc. Klinická onkologie. 2019;32(1):40-46. 193. Kovářová L, Szeligová L, Kissová J, et al. Stanovení diagnózy plazmocelulární leukémie v praxi. Klinická onkologie. 2008;21(Suppl.):258-260. 194. Dhakal B, Patel S, Girnius S, Bachegowda L, et al. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2021;35(7):2141. doi: 10.1038/s41375-021-01304-3. Erratum for: Leukemia. 2020 Dec;34(12):3338-3347. 195. Parrondo RD, Moustafa MA, Reeder C, et al. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(5):355360. doi:10.1016/j.clml.2021.01.002. 196. Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax,daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol. 2020;95(2):E34-E35. doi: 10.1002/ajh.25676. 197. Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis Blood. 2014(6):907-912. 198. Nandakumar B, Kumar SA, Dispenzieri A, et al. Clinical characteristics and outcomes of patients with primary plasma cell leukemia in the era of novel agent therapy Mayo Clin. Proc. 2021;96(3):677-687. 199. Sudo Y, Inagaki H. High-output heart failure associated with primary plasmancell leukaemia due to arteriovenous shunting: a case report. Eur Heart J Case Rep. 2021;5(9):ytab353. doi: 10.1093/ehjcr/ytab353 200. Zapletalová M, Krejčí D, Jarkovský J, et al. Epidemiology of plasma cell leukemia in the Czech Republic. Klinická onkologie. 2019;32(1):47-51. 201. Ciferská H, Vachek J. Diferenciální diagnostika bolestí zad. Vnitř. lék. 2022;68(5):332-341.
RkJQdWJsaXNoZXIy NDA4Mjc=